对乙酰氨基酚(Acetaminophen) - 药物靶点：COXs_在研适应症：镇痛，发热，疼痛_专利_临床

概要

基本信息

简介对乙酰氨基酚是一种常见的用于镇痛和退热的OTC药物，于1951 年获得美国食品和药物管理局 (FDA) 的批准，它的作用方式与经典的非甾体抗炎药 (NSAID) 非常相似，通过阻碍 COX-1 和 COX-2 酶的活性发挥作用。对乙酰氨基酚用于治疗轻度至中度疼痛、中度至重度疼痛与阿片类药物联用，或对抗发烧。它是一种常见的治疗多种疾病的药物，例如头痛、肌肉酸痛、关节炎、背痛、牙痛、喉咙痛、感冒、流感和发烧。这种药物有多种剂型，包括糖浆、常规和泡腾剂片剂、注射剂和栓剂。虽然主要是口服给药，但也可以静脉内给药。重要的是过量服用对乙酰氨基酚是危险的，甚至可能是致命的。服用时必须遵循正确剂量，如果过量服用立即就医。对乙酰氨基酚于无需处方即可广泛使用处方药或作为处方药。

药物类型

小分子化药

别名

4'-hydroxyacetanilide、4-(Acetylamino)phenol、4-ACETAMIDOPHENOL

+ [91]

靶点

COXs

作用方式

抑制剂

作用机制

COX抑制剂(环氧化酶抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Fresenius Kabi USA LLC

Terumo Corp.

丹东医创药业有限责任公司

+ [12]

非在研机构

Cosette Pharmaceuticals, Inc.

GSK Plc

McNeil Consumer & Specialty Pharmaceuticals, Inc.

+ [21]

权益机构

Seelos Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

中国 (1966-01-01),

发热疼痛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C8H9NO2

InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N

CAS号103-90-2

关联

1,655

项与对乙酰氨基酚相关的临床试验

NCT07101445

/ Not yet recruiting临床4期IIT

Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)

This phase IV trial compares the effect of premedication regimens with methylprednisolone versus dexamethasone for the prevention of allergic reaction to motixafortide in patients with multiple myeloma (MM) undergoing stem cell mobilization. MM patients that receive an autologous stem cell transplantation (ASCT) have better outcomes. However, not all MM patients are able to have a successful stem cell mobilization and collection which is needed to proceed to ASCT. The addition of motixafortide prior to stem cell mobilization has allowed more MM patients to collect the needed number of stem cells to proceed to ASCT. However, motixafortide does produce systemic and injection site reactions in many patients. A premedication regimen with dexamethasone prior to motixafortide decreases the incidence of allergic reaction in many patients and is considered the standard of care regimen for the prevention of allergic reaction to motixafortide in patients with MM undergoing stem cell mobilization. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen side effects/allergic reactions. However, dexamethasone is associated with other side effects like headache, difficulty sleeping, high blood glucose, high blood pressure, mood changes, fluid retention, and infection, among others. Thus, the optimal premedication regimen to prevent allergic reactions with motixafortide while avoiding other side effects remains uncertain. It is thought a premedication regimen with methylprednisolone prior to motixafortide may work better to decrease the incidence of reactions to motixafortide in patients with MM undergoing stem cell mobilization. Methylprednisolone is in a class of medications called corticosteroids. It works to decrease side effects/allergic reactions by changing the way the immune system works. Giving methylprednisolone may be safe, tolerable and/or more effective than dexamethasone as part of a premedication regimen for the prevention of allergic reaction to motixafortide in patients with MM undergoing stem cell mobilization.

开始日期2025-10-01

申办/合作机构

Emory University

[+1]

NCT07169227

/ Not yet recruiting临床4期IIT

The Comparison of the Efficacy of Lidocaine, Paracetamol, and Dexmedetomidine in Preventing Rocuronium Injection Pain

Propofol and rocuronium may cause pain during intravenous injection. Various pharmacological agents are used to reduce the incidence and severity of injection pain. Among the most commonly used agents for this purpose are lidocaine, various opioids, ketamine, paracetamol, and dexmedetomidine. The aim of this study was to evaluate the comparative effect of intravenous dexmedetomidine and paracetamol versus lidocaine in preventing propofol- and rocuronium-induced pain during anesthesia induction.

开始日期2025-09-01

申办/合作机构

Baskent University

NCT07024199

/ Recruiting临床4期IIT

Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children: a Randomized Trial

The aim of the study is to assess the effectiveness and tolerance of pain treatment in AP in children using intravenous paracetamol in combination with ibuprofen or paracetamol in combination with metamizole. The study is prospective, interventional, and randomized.

开始日期2025-09-01

申办/合作机构

Warszawski Uniwersytet Medyczny

100 项与对乙酰氨基酚相关的临床结果

登录后查看更多信息

100 项与对乙酰氨基酚相关的转化医学

登录后查看更多信息

100 项与对乙酰氨基酚相关的专利（医药）

登录后查看更多信息

50,305

项与对乙酰氨基酚相关的文献（医药）

2026-02-01·TISSUE & CELL

Ultrasonic irradiation for ZnO NPs Synthesis and their hepatoprotective effect against acetaminophen induced hepatic toxicity in albino rats: Biochemical, physiological, and histopathological assessments

Article

作者: Ismail, Sameh H ; Mahboub, Heba H ; Ezz-Eldin, Rasha M M ; Mansour, Yasmine A ; Youssef, Fady Sayed ; Mohamed, Gehad G ; Ibrahim, Sherin ; Hussein, Shaymaa ; Abdelfattah, Abdelfattah M ; AbdEl Halim, Hanan F

The present novel trial assesses the prophylactic influence of ZnO NPs in comparison to silymarin against liver damage induced by acetaminophen (APAP). Forty albino rats were allocated into 4 groups (n = `10 rats/ group). Group I (Control), was orally administered 0.9 % NaCl for 21 days. Group II (exposed to APAP) received distilled water (1 ml/kg per day) via oral gavage for 19 successive days followed by APAP (600 mg/kg, PO) twice daily for 2 days. Group III (APAP+ Silymarin) was orally administered silymarin at the dose of 200 mg/kg daily for 19 days followed by APAP (600 mg/kg) via oral gavage twice daily for 2 successive days. Group IV (APAP+ ZnO NPs) was orally given ZnO NPs at the dose of 100 mg/kg daily for 19 days followed by (600 mg/kg/ twice daily) APAP orally for 2 successive days. APAP exhibited a substantial elevation of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, nitric oxide and malondialdehyde levels. Meanwhile, APAP markedly decreased catalase, SOD, GST and TAC levels. A significant elevation in DNA damage inside hepatocytes was noticed. APAP induced many histopathological changes. Conversely, the prophylactic use of ZnO NPs inhibited the elevation of AST, ALT, ALP, NO and MDA as well as the decline of catalase, SOD, GST and TAC levels induced by APAP toxicity compared to group III. Marked improvement of the architecture of hepatic tissue was noticed in group IV. In conclusion, ZnO-NPs were more actual in ameliorating APAP hepatotoxicity compared to silymarin via antioxidant and antiapoptotic pathways.

2026-01-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Investigation of dielectric studies of paracetamol-diethylamine solutions: Experimental and machine learning approach

Article

作者: Jain, Prince ; Rana, V A ; Pandit, T R ; Prajapati, P M ; Thakor, Sanketsinh

This paper discusses about the dielectric studies of binary mixtures of paracetamol (PCM) and Diethylamine (DEA). Parallel resistance (R_p) and Parallel capacitance (C_p) measured using a precision LCR meter over a frequency range of 20 Hz-2 MHz at four distinct temperatures, starting from 293.15 K and increasing by 10 K for each subsequent measurement. These experimental parameters were used to compute the complex dielectric function, from which electrical properties like complex conductivity, complex impedance and complex electrical modulus-were derived. In addition to conventional analysis, machine learning (ML) models were implemented to predict dielectric constant (ε') and dielectric loss (ε″) values based experimental inputs, with their predictive performance significantly enhanced through Bayesian hyperparameter optimization. This dual approach of combining experimental data with ML modelling offers a novel methodology for efficient and accurate characterization of dielectric systems. The added value of this study lies in its ability to bridge physical measurements with computational predictions, reducing experimental workloads and improving generalization in similar systems. The findings have potential applications in material science, pharmaceuticals, and electronic device modelling. This study demonstrates that ML assisted dielectric analysis can serve as a powerful tool in predictive material characterization.

2026-01-01·TALANTA

Ergonomic and fully 3D–printed, activated, and modified electrochemical set–up for electroanalytical paracetamol detection

Article

作者: Poltorak, Lukasz ; Kowalski, Grzegorz ; Kwaczyński, Karolina

In this work, we manufactured the entire electrochemical configuration (all electrodes along with the ergonomic cell), which was 3D-printed using fused deposition modelling (FDM) technology. All electrodes were printed from carbon black/poly(lactic acid) (CB/PLA) filament, while the cell body was produced with neutral PLA. An activation process was conducted to enhance the electrochemical properties of all electrodes (working electrode (WE), counter electrode (CE), and reference electrode (RE)), which included immersion in dichloromethane followed by anodic, and cathodic treatment. The WE was only subjected to the activation process, providing the best output when the synergistic action of organic solvent and electrochemical electrode surface treatment were used. The novel aspects of this work originate from the applied electrode surface treatment, adjustment of all three electrodes' placement in an ergonomic and fully 3D printed cell, and finally, RE and CE properties adjustment. For the latter, the REs properties were defined by electrodeposition of silver particles further covered with AgCl, providing a stable and constant reference potential. The CE was made out of 3D-printed CB/PLA modified with platinum particles, which enhanced its electric conductivity. Even though, in both cases, the surface coverage was found to be nonhomogeneous the electrodes displayed desired properties, creating cheap substitutions to commercially available components. All electrodes were comprehensively inspected with a range of characterization techniques, including voltammetry, chronoamperometry, electrochemical impedance spectroscopy, scanning electron microscopy, optical profilometry, attenuated total reflectance Fourier-transform infrared spectroscopy, laser-induced breakdown spectroscopy along with surface wettability studies. The electrochemical behavior of the system, in the presence of a model redox probe, ferrocenemethanol, was analyzed using cyclic voltammetry. Finally, our fully 3D-printed sensing platform was assessed for paracetamol determination giving the limit of detection and limit of quantification to be 0.38 μM and 1.26 μM, respectively. The system was successfully applied to the determination of paracetamol in a pharmaceutical tablet using the standard addition method, confirming its suitability for quantitative analysis in complex sample matrices.

1,054

项与对乙酰氨基酚相关的新闻（医药）

2025-09-12

·梅斯医学

喂完退烧药宝宝吐了，要不要再喂一次？看看最新共识和研究怎么说

儿童发热是临床常见症状，合理使用退烧药对改善患儿舒适度和防止严重并发症至关重要。布洛芬和对乙酰氨基酚作为首选退热药，长期以来被广泛应用。但关于两药是否可以联合或交替使用，临床上存在争议。本文结合最新专家共识及临床研究，帮助医生科学合理选择和使用退烧药，保障患儿安全。01退烧药的选择2个月以上体温≥38.2℃且有明显不适时，可考虑使用退烧药。推荐首选对乙酰氨基酚或布洛芬。不推荐使用安乃近、乙酰水杨酸、阿司匹林等其他药物，也不推荐糖皮质激素作为退热剂。02 喂药后呕吐的处理如果孩子体温仍高且不适，且呕吐发生在服药后数分钟且吐出较多药物量，可考虑补服退烧药，补充用量应控制在安全范围内。呕吐发生时间较长或呕吐量少，建议观察等待药效，不轻易重复用药，避免药物过量。频繁呕吐伴脱水风险时，优先选择对乙酰氨基酚，因其胃肠刺激较小。对乙酰氨基酚需间隔不少于4小时，布洛芬不少于6小时服用。03 对乙酰氨基酚与布洛芬的联合或交替使用《解热镇痛药在儿童发热对症治疗中的合理用药专家共识》中明确指出，不推荐联合或交替使用，理由是两药作用机制相似，联合用药无明显提升舒适度，且增加不良反应风险。同时，《解热镇痛药在儿童发热对症治疗中处方审核建议》也提到，虽然有文献报道对乙酰氨基酚联合布洛芬降低体温较单药治疗效果要好，但临床意义尚不明确。去年Pediatrics杂志发表了一项Meta分析纳入5009名儿童数据，显示联合或交替用药确实在服药初期4~6小时内退热效果优于单药治疗，且短期安全性相似。高剂量布洛芬退热效果与联合/交替用药相当。不良事件发生率无显著差异。04 诊断标准与用药指征体温≥38.2℃伴明显不适时，考虑药物退热。药物剂量应严格按照体重计算，避免按年龄简化用药。05 用药剂量与间隔对乙酰氨基酚：10-15 mg/kg，每4小时一次，24小时内不超过5次。布洛芬：7.5-10 mg/kg，每6-8小时一次，24小时内不超过4次。06 特殊人群注意频繁呕吐和脱水风险儿童优先选择对乙酰氨基酚。肝肾功能异常患者应谨慎使用，对乙酰氨基酚需严控剂量。总之，尽管传统观点反对联合或交替使用，但新Meta分析提供了有力证据支持其短期安全有效，提示临床医生可根据实际患儿情况灵活用药。同时强调精确剂量和监控用药安全的重要性。专家们呼吁未来更多高质量临床研究，以评估长期安全性及最佳用药策略。来源 | 梅斯医学综合整理编辑 | rayms授权转载及爆料请联络梅斯医学管理员点击下方“阅读原文” 下载梅斯医学APP吧！

临床结果

2025-09-12

·ETPharma

Kenvue CEO lobbied RFK Jr. not to cite Tylenol as autism cause, WSJ reports

Bengaluru: Kenvue's interim CEO Kirk Perry met Robert F. Kennedy Jr. to try and dissuade him from listing Tylenol as a potential cause of autism in an upcoming report, the Wall Street Journal said on Friday, citing a person familiar with the matter. Perry argued at the hastily scheduled meeting this week that there was no clear link between the two, the report said. WSJ reported on September 5 that the U.S. health secretary planned to announce that the use of Tylenol, a popular over-the-counter pain medication, in pregnant women was potentially linked to autism - contrary to medical guidelines that say it is safe to use. Kenvue shares fell more than 9% to $18.62 after the report last week, but have since recovered slightly. The U.S. Department of Health and Human Services did not immediately respond to a Reuters request for comment. As we would with any regulator who reaches out to us, we engaged in a scientific exchange with the secretary and members of his staff as it relates to the safety of our products, Kenvue said in an emailed response. The company said it continues to believe that taking acetaminophen - the active ingredient in Tylenol - does not cause autism and that global health regulators, independent public health organizations and medical professionals agreed. Kenvue executives have also argued that there are few safe alternatives to acetaminophen to reduce fevers in pregnant women, according to the WSJ report. According to researchers, there is no firm evidence of a link between the use of the drug and autism. Recent studies have yielded conflicting conclusions on whether its use during pregnancy might create risks for the developing fetus. Wall Street analysts view Kenvue as an acquisition target after it came under pressure from investors, who have criticized its lackluster performance. (Reporting by Sriparna Roy and Sneha S K in Bengaluru; Editing by Pooja Desai)

并购

2025-09-12

·医脉通

发热乏力为首发，13岁少女B细胞淋巴瘤合并严重并发症一例

医脉通-临床病例平台医脉通临床病例平台，为医生保留的病例交流线上站，快来一起讨论，共同学习。病例介绍患儿，女，13岁，因“间断发热5天，胸闷乏力4天”入院。患儿于入院前5天无明显诱因下出现发热，未测体温，伴畏寒，无寒战，无咳嗽，予“感冒灵颗粒、复方氨酚烷胺胶囊、头孢克肟”口服2天，患儿体温下降正常，病程第二天出现出现胸闷、全身乏力和头晕不适，纳差，无晕厥，无头痛，无呕吐，无腹泻，无腹痛，无皮疹，无四肢关节疼痛，未就诊。今晨起再次发热，体温达40.5℃，伴阵发性干咳，无口后发绀，口服“对乙酰氨基酚”退热，体温可下降正常，但有反复，遂至当地医院就诊，就诊过程中患儿双侧鼻出血，量少，完善“血常规：白细胞0.81x109/L，红细胞2.06x1012/L，血红蛋白59g/L，血小板计数46x109/L，中性粒细胞绝对值0.58x109/L”，考虑患儿病情危重，建议上级医院就诊，遂来我院就诊，门诊以“三系减少”查因收入院。起病来，患儿精神、食纳欠佳，睡眠可，二便正常。既往体健，家族史、个人史无异常。患儿，女，13岁，因“间断发热5天，胸闷乏力4天”入院。患儿于入院前5天无明显诱因下出现发热，未测体温，伴畏寒，无寒战，无咳嗽，予“感冒灵颗粒、复方氨酚烷胺胶囊、头孢克肟”口服2天，患儿体温下降正常，病程第二天出现出现胸闷、全身乏力和头晕不适，纳差，无晕厥，无头痛，无呕吐，无腹泻，无腹痛，无皮疹，无四肢关节疼痛，未就诊。今晨起再次发热，体温达40.5℃，伴阵发性干咳，无口后发绀，口服“对乙酰氨基酚”退热，体温可下降正常，但有反复，遂至当地医院就诊，就诊过程中患儿双侧鼻出血，量少，完善“血常规:白细胞0.81x109/L，红细胞2.06x1012/L，血红蛋白59g/L，血小板计数46x109/L，中性粒细胞绝对值0.58x109/L”，考虑患儿病情危重，建议上级医院就诊，遂来我院就诊，门诊以“三系减少”查因收入院。起病来，患儿精神、食纳欠佳，睡眠可，二便正常。既往体健，家族史、个人史无异常。 ➤体格检查 T 39.8℃，P 139 次/分，R 23次/分，wt 50.0kg，BP 96/50mmHg，SPO2 99%（鼻导管输氧下）神志清楚，精神差，营养良好，急性面容，重度贫血貌，皮肤黏膜无黄染，无肝掌、蜘蛛痣，巩膜无黄染，浅表淋巴结无肿大，颈软。双侧球结膜无充血，双侧瞳孔等大、等圆，直径约3mm大小，对光反射灵敏，面色口唇苍白，呼吸规则，未见三凹征，双肺呼吸音粗，未闻及啰音，心率139次/分，相齐，无杂音，腹壁柔软，肝脾不大，无压痛及反跳痛，未触及腹部包块，肠鸣音可，双下肢活动可，四肢末端暖，CRT 2-3秒。 ➤实验室检查 2025-05-16危入院时血常规：白细胞0.43x109/L，红细胞 1.90x1012/L，血红蛋白55.00g/L，血小板计数46.00x109/L，淋巴细胞百分比20.90%，中性粒细胞百分比76.80%，淋巴细胞绝对值0.09x109/L，中性粒细胞绝对值0.33x109/L，网织红细胞百分比1.66%。 2025-05-17输血科检验报告：Rh血型阳性，血型鉴定O型。凝血常规：凝血酶原时间15.00秒，国际标准化比值1.31，活化部分凝血酶原时间26.10秒，凝血酶时间测定18.1秒，纤维蛋白原2.53g/L，D-二聚体定量19.23mg/L。心肝肾功能血脂常规：间接胆红素 16.70μmol/L，谷丙转氨酶24.40U/L，谷草转氨酶48.50U/L，总胆红素28.90μmol/L，直接胆红素 12.20μmol/L，总蛋白 53.90g/L，白蛋白 36.50g/L，球蛋白 17.40g/L，总胆汁酸 17.00μmol/L；尿素 4.61mmol/L，肌酐 71.20μmol/L，尿酸 300.20μmol/L；乳酸脱氢酶 437.50U/L，肌酸激酶140.000/L，肌酸激酶同工酶13.00U/L，肌红蛋白54.10μg/L；甘油三酯 0.69mmol/L，总胆固醇2.26mmol/L，高密度脂蛋白胆固醇0.44mmol/L，低密度脂蛋白胆固醇1.34mmol/L；葡萄糖6.37mmol/L。C-反应蛋白 21.30mg/L。类风湿因子<9.6310/mL，抗链球菌溶血素O 298.00IU/mL。免疫球蛋白G 10.80g/L，免疫球蛋白A 2.02gL，免疫球蛋白M 1.49g/L，补体C3 1.02g/L，补体C4 0.24g/L。心电图检查报告：1.窦性心动过速，2.电轴正常。心脏超声检查报告：检查结果二三尖瓣轻度返流。腹部彩超：检查结果右下腹阑尾区暂未探及明显肿大阑尾声像。头部+肺部+腹部CT：1.双肺炎症，建议治疗后复查。2.肝大、牌大及腹膜后多发增大淋巴结，请结合临床。3.盆腔少量积液。4.头颅CT平扫未见明显异常。 2025-05-19血液肿瘤检验报告：T抑制/毒性淋巴细胞百分比(%)15.79，T辅助/诱导淋巴细胞百分比(%)33.83%，T淋巴细胞百分比(%) 57.14%，B淋巴细胞百分比(%)30.34%↑，NK淋巴细胞百分比(%)6.19%，CD3+CD4+CD8+(%)0%，T辅助/控制细胞比2.14，T淋巴细胞绝对计数50.00μl↓，T辅助/请导淋巴细胞绝对计数29.00μl↓，T抑制/毒性淋巴细胞绝对计数14.00μl，B淋巴细胞绝对计数59.00μl，NK淋巴细胞绝对计数 12.00μl↓，CD3+CD4+CD8+绝对计数，提示T细胞明显降低。呼吸道多种病原体靶向测序，单纯疱疹病毒1型(HSV-1)均化学列数。 2025-05-21血常规:白细胞1.93x109/L，红细胞2.99x1012/L，血红蛋白89.00g/L，血小板计数143.00x109/L，淋巴细胞百分比56.50%，中性粒细胞百分比41.40%。外送金域检查：sCD25：52131pg/mL，NK细胞活性：9.78%。 2025-05-23骨髓活检结果提示用合免疫组化，符合B细胞淋巴瘤(瘤细胞约占305，MF-1级)。流式结果：未检测到明显异常的髓系原始细胞，可见约3.72%，CD5阴性，CD10 阳性，异常成熟小B淋巴细胞。欢迎讨论该患儿的主要并发症是什么？谈谈其诊断标准及你的诊断依据（查看原文参与互动讨论）审校：ZTL 排版：Zelda 执行：Zelda END 点击 [阅读原文] 进入原病例参与讨论，您的临床思考将为医学实践注入更多鲜活洞见！

临床研究

100 项与对乙酰氨基酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00217	对乙酰氨基酚	N02BE01	DB00316

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
头痛	美国	Cosette Pharmaceuticals, Inc.	1978-02-09
镇痛	日本	Iwaki Seiyaku Co., Ltd.	1966-07-01
发热	中国	丹东医创药业有限责任公司	1966-01-01
疼痛	中国	丹东医创药业有限责任公司	1966-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
牙痛	临床3期	美国	Johnson & Johnson Holdco (NA), Inc.	2017-07-19
普通感冒	临床3期	-	GSK Plc	2017-02-01
咽炎	临床3期	-	GSK Plc	2017-02-01
发作性紧张型头痛	临床3期	美国	GSK Plc	2013-04-01
急性疼痛	临床3期	美国	Mallinckrodt Plc	2008-01-01
术后疼痛	临床3期	美国	Mallinckrodt Plc	2006-11-01
子宫癌	临床3期	美国	Mallinckrodt Plc	2006-11-01
急性偏头痛	临床3期	美国	Merck Sharp & Dohme Corp.	2006-03-01
髋关节炎	临床3期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2005-10-18
糖尿病性神经病变	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2003-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03365622 (CTgov)	临床4期	-	214	Placebo Oral Tablet+acetaminophen (IV Acetaminophen and Placebo Pills)	艱壓選簾糧構糧網願遞(築糧餘襯選顧齋願餘製) = 觸醖築淵夢衊膚網淵壓鏇糧鑰鑰網鬱窪淵襯網 (鏇製觸積築鹽齋築顧齋, 58.16) 更多	-	2025-06-29
				Placebos+Acetaminophen (Placebo IV (Normal Saline) + Oral Acetaminophen)	艱壓選簾糧構糧網願遞(築糧餘襯選顧齋願餘製) = 鑰顧築網淵餘廠鑰顧積鏇糧鑰鑰網鬱窪淵襯網 (鏇製觸積築鹽齋築顧齋, 57.59) 更多
NCT02356159 (CTgov)	临床1/2期	霍奇金淋巴瘤 \| 多发性骨髓瘤 \| 急性白血病 ... 更多	34	Epinephrine+PET+Acetaminophen+prednisone+EPOCH-F+Palifermin+Diphenhydramine+Rituximab (2/Phase II Arm - Palifermin at the Recommended Phase 2 Dose)	餘築餘夢餘壓淵範積選 = 窪範糧積艱憲鹽窪醖膚簾範壓顧窪餘廠壓衊襯 (積鹹蓋獵糧艱衊遞衊糧, 觸選鹽廠襯獵夢壓鏇遞 ~ 蓋醖鏇鑰鏇憲淵衊獵夢)	-	2025-06-05
				Epinephrine+PET+Acetaminophen+prednisone+EPOCH-F+Palifermin+Diphenhydramine+Rituximab (1/Phase 1: Dose Escalation Arm - Palifermin)	壓選窪糧範顧壓鑰遞繭 = 衊顧鹹廠簾鹽醖顧糧範膚齋鏇膚糧鹽夢觸獵憲 (製鏇齋襯獵窪窪襯憲艱, 願積鑰夢淵網淵壓遞憲 ~ 壓襯範簾廠觸觸構窪獵)
NCT04574778 (Pubmed \| Reg Anesth Pain Med) 人工标引	临床3期	术后疼痛	82	Intravenous acetaminophen	鬱鹽鏇觸鑰襯顧範鏇願(衊壓觸簾襯廠鬱網鏇糧) = 繭製壓鏇艱衊蓋觸蓋鏇獵膚遞艱鹽糧繭鏇壓壓 (鏇窪範壓範鑰願夢鏇鏇, 4.0 ~ 27.1)	不佳	2025-06-01
				Oral acetaminophen	鬱鹽鏇觸鑰襯顧範鏇願(衊壓觸簾襯廠鬱網鏇糧) = 膚製齋鏇獵簾窪範築襯獵膚遞艱鹽糧繭鏇壓壓 (鏇窪範壓範鑰願夢鏇鏇, 4.0 ~ 29.5)
ATS2025	N/A	脓毒症 baseline plasma IL-8 \| sTNFR1 \| serum bicarbonate ... 更多	447	Acetaminophen (Hyperinflammatory Phenotype)	構夢廠鬱糧廠獵觸窪淵(蓋壓觸觸壓築膚鹽構鬱) = 齋窪範鹽網鹹鬱衊範衊淵憲夢顧艱齋鹹窪獵鹽 (鏇廠壓壓餘餘衊鏇夢艱 ) 更多	不佳	2025-05-16
				Acetaminophen (Hypoinflammatory Phenotype)	構夢廠鬱糧廠獵觸窪淵(蓋壓觸觸壓築膚鹽構鬱) = 製獵艱餘鹹遞繭觸壓衊淵憲夢顧艱齋鹹窪獵鹽 (鏇廠壓壓餘餘衊鏇夢艱 ) 更多
NCT00585559 (CTgov)	临床3期	颅内动脉瘤1 \| 颅内血管痉挛	44	N-acetylcysteine (N-acetylcysteine IV Infusion at 0.5 gm Hourly)	衊鏇簾齋艱壓鑰積夢壓(廠膚鏇繭壓網齋憲鏇獵) = 積製鏇壓積艱齋襯餘餘獵網築襯構醖窪鏇鹹窪 (構鏇鹹衊遞鑰襯襯鹽淵, 憲齋廠繭廠醖構製願觸 ~ 鬱選簾鹹鹹艱製鹹顧夢) 更多	-	2025-04-18
				Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly)	衊鏇簾齋艱壓鑰積夢壓(廠膚鏇繭壓網齋憲鏇獵) = 鹹遞艱選築鬱繭獵網蓋獵網築襯構醖窪鏇鹹窪 (構鏇鹹衊遞鑰襯襯鹽淵, 鹽膚鹽網鏇窪範壓鹹齋 ~ 願積醖糧醖蓋選獵簾糧) 更多
NCT05647681 (Pubmed \| Pain Med)	临床1期	软组织损伤	-	Paracetamol	選膚糧觸鏇簾淵製蓋願(鬱齋簾築範網鬱製蓋艱) = 繭淵繭鏇衊窪壓網簾簾範願襯壓製製餘膚醖窪 (鏇壓範廠齋淵選製鏇鏇 ) 更多	积极	2025-03-05
NCT05974501 (CTgov)	临床4期	关节置换术并发症 \| 膝关节炎 \| 术后疼痛	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	鑰衊鏇膚鹹顧壓繭觸衊(鏇鏇製蓋選廠衊鬱獵餘) = 鹽鬱簾鹹遞遞觸窪糧鑰簾築簾齋鏇簾衊觸鹹廠 (襯網鬱憲選醖簾壓願壓, 糧願製網鑰蓋窪鏇夢構 ~ 襯艱艱艱願鏇繭鑰網獵) 更多	-	2025-02-12
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	鑰衊鏇膚鹹顧壓繭觸衊(鏇鏇製蓋選廠衊鬱獵餘) = 簾繭淵築夢鏇築壓鏇願簾築簾齋鏇簾衊觸鹹廠 (襯網鬱憲選醖簾壓願壓, 夢簾糧艱繭簾積鹽夢遞 ~ 壓糧網鬱願積築顧淵繭) 更多
NCT06601114 (Pubmed \| Mol Cell Pediatr)	N/A	动脉导管未闭	256	Paracetamol	膚積襯願艱鏇遞選膚鑰(選淵簾膚顧範簾齋鏇鹽) = 遞築膚構蓋積淵積鹽築獵衊淵網積醖顧糧廠餘 (襯艱製糧齋鑰憲鏇淵積 )	积极	2025-01-25
				Ibuprofen	膚積襯願艱鏇遞選膚鑰(選淵簾膚顧範簾齋鏇鹽) = 築鬱觸構淵齋積廠鬱積獵衊淵網積醖顧糧廠餘 (襯艱製糧齋鑰憲鏇淵積 )
NCT03987022 (CTgov)	临床4期	术后疼痛	66	Opioids+Dilaudid Injectable Product+Percocet 5Mg-325Mg Tablet+Motrin	艱製製鬱範衊衊範醖築(觸艱糧蓋顧壓網壓壓鏇) = 繭願窪鹽艱淵鏇鏇窪廠鹹選鏇構襯醖鬱糧衊壓 (選憲製夢膚顧構窪鏇憲, 淵簾製簾膚製製鏇積壓 ~ 顧蓋選獵廠選蓋網糧齋)	-	2025-01-24
NCT04291508 (ASTER, CTgov)	临床2期	呼吸衰竭 \| 危重病 \| 脓毒症 ... 更多	488	Acetaminophen (IV Acetaminophen-Active)	鬱艱襯顧餘鹹夢襯鹽鬱(淵選廠壓壓選網醖繭構) = 壓構鏇鏇繭鑰艱鑰鹽觸膚窪鬱糧窪鏇夢壓艱鬱 (構襯衊衊顧廠蓋憲範窪, 10.6) 更多	-	2024-09-27
				Intravenous Vitamin C (refrigerated) (IV Vitamin C-Active)	鬱艱襯顧餘鹹夢襯鹽鬱(淵選廠壓壓選網醖繭構) = 鹽鑰鑰製夢觸夢窪鏇夢膚窪鬱糧窪鏇夢壓艱鬱 (構襯衊衊顧廠蓋憲範窪, 9.5) 更多